Kramer H K, Simon E J
Department of Psychiatry, New York University Medical Center, New York 10016, USA.
J Neurochem. 1999 Feb;72(2):585-93. doi: 10.1046/j.1471-4159.1999.0720585.x.
Agonist-induced down-regulation of opioid receptors appears to require the phosphorylation of the receptor protein. However, the identities of the specific protein kinases that perform this task remain uncertain. Protein kinase C (PKC) has been shown to catalyze the phosphorylation of several G protein-coupled receptors and potentiate their desensitization toward agonists. However, it is unknown whether opioid receptor agonists induce PKC activation under physiological conditions. Using cultured SH-SY5Y neuroblastoma cells, which naturally express mu- and delta-opioid receptors, we investigated whether mu-opioid receptor agonists can activate PKC by measuring enzyme translocation to the membrane fraction. PKC translocation and opioid receptor densities were simultaneously measured by 3H-phorbol ester and [3H]diprenorphine binding, respectively, to correlate alterations in PKC localization with changes in receptor binding sites. We observed that mu-opioid agonists have a dual effect on membrane PKC density depending on the period of drug exposure. Exposure for 2-6 h to [D-Ala2,N-Me-Phe4,Gly-ol]enkephalin or morphine promotes the translocation of PKC from the cytosol to the plasma membrane. Longer periods of opioid exposure (>12 h) produce a decrease in membrane-bound PKC density to a level well below basal. A significant decrease in [3H]diprenorphine binding sites is first observed at 2 h and continues to decline through the last time point measured (48 h). The opioid receptor antagonist naloxone attenuated both opioid-mediated PKC translocation and receptor down-regulation. These results demonstrate that opioids are capable of activating PKC, as evidenced by enhanced translocation of the enzyme to the cell membrane, and this finding suggests that PKC may have a physiological role in opioid receptor plasticity.
激动剂诱导的阿片受体下调似乎需要受体蛋白的磷酸化。然而,执行此任务的特定蛋白激酶的身份仍不确定。蛋白激酶C(PKC)已被证明可催化几种G蛋白偶联受体的磷酸化并增强它们对激动剂的脱敏作用。然而,在生理条件下阿片受体激动剂是否会诱导PKC激活尚不清楚。我们使用天然表达μ-和δ-阿片受体的培养的SH-SY5Y神经母细胞瘤细胞,通过测量酶向膜部分的转位来研究μ-阿片受体激动剂是否能激活PKC。分别通过3H-佛波酯和[3H]二丙诺啡结合同时测量PKC转位和阿片受体密度,以将PKC定位的变化与受体结合位点的变化相关联。我们观察到,μ-阿片激动剂对膜PKC密度有双重影响,这取决于药物暴露的时间。暴露于[D-Ala2,N-Me-Phe4,Gly-ol]脑啡肽或吗啡2-6小时可促进PKC从细胞质向质膜的转位。更长时间的阿片暴露(>12小时)会使膜结合的PKC密度降低至远低于基础水平。在2小时时首次观察到[3H]二丙诺啡结合位点的显著降低,并在测量的最后一个时间点(48小时)持续下降。阿片受体拮抗剂纳洛酮减弱了阿片介导的PKC转位和受体下调。这些结果表明,阿片类药物能够激活PKC,这通过酶向细胞膜的转位增强得到证明,这一发现表明PKC可能在阿片受体可塑性中具有生理作用。